Almirall SA (ALM.MC) stock: key figures, P/E, revenue and dividend
Health Care · Spain · ISIN ES0157097017
Almirall SA financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 985.00 m EUR | 1.11 bn EUR |
| Gross profit | 767.00 m EUR | 456.00 m EUR |
| Operating income | 50.52 m EUR | 71.89 m EUR |
| EBIT | 36.00 m EUR | 67.00 m EUR |
| Net income | 10.00 m EUR | 46.00 m EUR |
| Diluted EPS – continuing operations | 0.05 EUR | 0.22 EUR |
Full history since 2003, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Almirall SA
Almirall, S.A. operates as a skin health-focused biopharmaceutical company in Spain, Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising Psoriasis, atopic dermatitis, acne, actinic keratosis, onychomycosis, androgenic alopecia, oncodermatology, and orphan indications, as well as for alimentary tract and metabolism, anti-infective for systemic use, cardiovascular system, dermatological, genito urinary system and sex hormones, immunostimulants, metabolism, musculo-skeletal system, nervous system, respiratory system, systemic hormonal preparations. It also develops tirbanibulin for actinic keratosis, and tildrakizumab for psoriatic arthritis under the registration phase, as well as lebrikizumab for atopic dermatitis pediatric in phase 2; Anti-IL-1RAP mAb for hidradenitis suppurativa, anti-IL-1RAP mAb for inflammatory skin disease, Anti-IL-21 mAb for hidradenitis suppurativa, IL-2muFc for alopecia areata, IL-2muFc for atopic dermatitis, and IL-2muFc for inflammatory skin disease in phase 2; readthrough inducer for rare dermatology in phase 1; and anti-IL-13/OX40L BsAb for atopic dermatitis, SMOL oral for Th2-driven diseases, and mRNA/LNP for non-melanoma skin cancer in preclinical stage. It has research and development agreements with Evotec, Ichnos, Simcere, Etherna, Novo Nordisk, and Eloxx. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.
More stocks
- PSK Inc (319660.KQ)
- Home Product Center Public Company Limited (HMPRO.BK)
- Shanghai Tunnel Engineering Co Ltd (600820.SS)
- Charoen Pokphand Indonesia TBK PT (CPIN.JK)
- Koninklijke Heijmans N.V. (HEIJM.AS)
- BLACKBAUD INC (BLKB)
- CENTRAL GARDEN & PET CO (CENTA)
- Vusion SA (VU.PA)
- Renewables Infrastructure Group Ltd (TRIG.L)
- Guangdong Dongfang Precision Science & Technology Co Ltd (002611.SZ)
- Zhejiang Provincial New Energy Investment Group Co Ltd (600032.SS)
- HUTCHMED DRC (HCM)
Not investment advice. All data without warranty, price as of 22.10.2026. Details in the risk notice.